Medigene AG has selected its lead candidate for MDG-2021, a T-cell receptor engineered T-cell (TCR-T) therapy targeting KRAS G12D with human leukocyte antigen (HLA)-A*11 being developed in combination with the company’s PD1-41BB costimulatory switch protein (CSP) technology.